Discovery of new pyridine heterocyclic hybrids; design, synthesis, dynamic simulations, and in vitro and in vivo breast cancer biological assays

Pyridine is a nitrogen bearing heterocyclic scaffold that shows a wide range of biological activities. The pyridine nucleus has become an interesting target for medicinal chemistry researchers worldwide. Several pyridine derivatives exhibited good anticancer effects against diverse cell lines. Therefore, to explore new anticancer pyridine entities, novel pyridine derivatives were designed and synthesized and evaluated for their anticancer abilities in vitro and in vivo. All of the target compounds were evaluated against three different human cancer cell lines (Huh-7, A549 and MCF-7) via MTT assay. Most of the compounds exhibited significant cytotoxic activities. Compounds 3a, 3b, 5a and 5b showed superior antiproliferative activities to Taxol. Where, compound 3b showed IC50 values of 6.54, 15.54 and 6.13 μM compared to Taxol (6.68, 38.05, 12.32 μM) against Huh-7, A549 and MCF-7, respectively. Also, tubulin polymerization assay was carried out. The most potent compounds 3a, 3b, 5a and 5b could significantly inhibit tubulin polymerization with IC50 values of 15.6, 4.03, 6.06 and 12.61 μM, respectively. Compound 3b exhibited the highest tubulin polymerization inhibitory effect with an IC50 value of 4.03 μM compared to combretastatin (A-4) (1.64 μM). Molecular modeling studies of the designed compounds confirmed that most of the compounds made the essential binding interactions compared to the reference compound which assisted in the prediction of the structure requirements for the detected anticancer activity. Finally, in vivo studies showed that compound 3b could significantly inhibit breast cancer.

[1]  Donghee Kim,et al.  Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease , 2022, Clinical and molecular hepatology.

[2]  H. Cortez‐Pinto,et al.  Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors , 2022, Nature reviews. Gastroenterology & hepatology.

[3]  Salahuddin,et al.  Pyridine moiety: An insight into recent advances in treatment of cancer. , 2021, Mini reviews in medicinal chemistry.

[4]  Ting Zhu,et al.  Progress of tubulin polymerization activity detection methods. , 2021, Bioorganic & medicinal chemistry letters.

[5]  Mohamed S. Nafie,et al.  Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells. , 2020, Bioorganic & medicinal chemistry.

[6]  J. Dimmock,et al.  Discovery and investigation of 1-[4-(2-aminoethoxy)phenylcarbonyl]-3,5-bis-(benzylidene)-4-piperidones as candidate antineoplastic agents: Our last 15 years study. , 2020, Current medicinal chemistry.

[7]  E. Sobarzo-Sánchez,et al.  Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications , 2020, Molecules.

[8]  Surajit Ghosh,et al.  In silico ADMET study, docking, synthesis and antimalarial evaluation of thiazole-1,3,5-triazine derivatives as Pf-DHFR inhibitor , 2019, Pharmacological reports : PR.

[9]  J. Quiles,et al.  Modulation by hydroxytyrosol of oxidative stress and antitumor activities of paclitaxel in breast cancer , 2019, European Journal of Nutrition.

[10]  Yan-Ting Wang,et al.  Synthesis, biological evaluation and molecular docking of benzimidazole grafted benzsulfamide-containing pyrazole ring derivatives as novel tubulin polymerization inhibitors. , 2019, Bioorganic & medicinal chemistry.

[11]  D. Sriram,et al.  Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations , 2018, Journal of biomolecular structure & dynamics.

[12]  G. Dehghan,et al.  Cytotoxicity, oxidative stress, and apoptosis in K562 leukemia cells induced by an active compound from pyrano-pyridine derivatives , 2018, Human & experimental toxicology.

[13]  Honghao Sun,et al.  Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures. , 2017, Future medicinal chemistry.

[14]  A. Cavalli,et al.  Structural Basis of cis- and trans-Combretastatin Binding to Tubulin , 2017 .

[15]  E. De Clercq,et al.  Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones. , 2016, Bioorganic & medicinal chemistry.

[16]  G. Francia,et al.  A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells , 2016, Cellular Oncology.

[17]  Danzhou Yang,et al.  A New G-Quadruplex with Hairpin Loop Immediately Upstream of the Human BCL2 P1 Promoter Modulates Transcription. , 2016, Journal of the American Chemical Society.

[18]  G. Bérubé.  An overview of molecular hybrids in drug discovery , 2016, Expert opinion on drug discovery.

[19]  J. Tuszynski,et al.  The Unique Binding Mode of Laulimalide to Two Tubulin Protofilaments , 2015, Chemical biology & drug design.

[20]  K. Abouzid,et al.  Newly Designed and Synthesized Curcumin Analogs with in vitro Cytotoxicity and Tubulin Polymerization Activity , 2015, Chemical biology & drug design.

[21]  K. Abouzid,et al.  Design, synthesis and biological evaluation of Novel Curcumin Analogs with anticipated anticancer activity , 2015 .

[22]  Feroz Khan,et al.  Natural antitubulin agents: importance of 3,4,5-trimethoxyphenyl fragment. , 2015, Bioorganic & medicinal chemistry.

[23]  Keke Li,et al.  Design, Synthesis and Bioevaluation of Novel N‐Substituted‐3,5‐Bis(Arylidene)‐4‐piperidone Derivatives as Cytotoxic and Antitumor Agents with Fluorescent Properties , 2014, Chemical biology & drug design.

[24]  M. Djamgoz,et al.  Oxidative Stress in the in vivo DMBA Rat Model of Breast Cancer: Suppression by a Voltage‐gated Sodium Channel Inhibitor (RS100642) , 2012, Basic & clinical pharmacology & toxicology.

[25]  Duane D. Miller,et al.  An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site , 2012, Pharmaceutical Research.

[26]  A. Shafiee,et al.  Asymmetrical 2,6-bis(benzylidene)cyclohexanones: Synthesis, cytotoxic activity and QSAR study. , 2012, European journal of medicinal chemistry.

[27]  M. Al-Omar,et al.  Synthesis, antiplatelet aggregation activity, and molecular modeling study of novel substituted-piperazine analogues , 2011, Medicinal Chemistry Research.

[28]  Erik A. A. Wallén,et al.  Inhibitors and promoters of tubulin polymerization: synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents. , 2011, Bioorganic & medicinal chemistry.

[29]  R. Sharma,et al.  1,5-diaryl-3-oxo-1,4-pentadienes: a case for antineoplastics with multiple targets. , 2009, Current medicinal chemistry.

[30]  I. W. Cheney,et al.  Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. , 2007, Bioorganic & medicinal chemistry letters.

[31]  D. Lesieur,et al.  Docking Study of Ligands into the Colchicine Binding Site of Tubulin , 2004, Journal of enzyme inhibition and medicinal chemistry.

[32]  Masahide Kikkawa,et al.  Dynein and kinesin share an overlapping microtubule‐binding site , 2004, The EMBO journal.

[33]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[34]  Patrick A. Curmi,et al.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain , 2004, Nature.

[35]  Arun K. Ghosh,et al.  The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. , 2002, Biochemistry.

[36]  F. Badria,et al.  Synthesis and biological evaluation of certain α, β-unsaturated ketones and their corresponding fused pyridines as antiviral and cytotoxic agents , 2000 .

[37]  E. De Clercq,et al.  Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds. , 2007, European journal of medicinal chemistry.